This document contains usage analytics for a website related to the ICHNO 2013 conference from January 11 to February 10, 2013. It provides statistics on total site usage, top pages viewed, and the most viewed presentations. The top 3 pages were the E-Poster Viewer gallery, the E-poster submission page, and the general E-Poster viewer. The most viewed presentation was on cisplatin and 5-FU induction chemotherapy followed by chemoradiotherapy for advanced nasopharyngeal carcinoma, with 96 views.

1. ICHNO 2013
Usage Analytics
11 January 2013 – 10 February 2013
02.04.2012

2. Users Statistics
Site Usage
11 January 2013 – 10 February 2013
2

3. Users Statistics
Page Views
11 January 2013 – 10 February 2013
3

4. Users Statistics
Page Views
11 January 2013 – 10 February 2013
Top Pages Viewed:
1. E-Poster Viewer – Gallery View: 1131 page views
2. E-poster Submission: 301 page views
3. E-Poster Viewer: 246 page views
4

5. Users Statistics
Page Views – Most Viewed Presentations
11 January 2013 – 10 February 2013
Presentation Page Unique Avg.
views Page Time on
views Page
Cisplatin and 5-FU induction chemotherapy followed by chemoradiotherapy in advanced 96 89 10.92
nasopharyngeal carcinoma
Combined reirradiation and cetuximab for locally recurrent head and neck cancer – mature 27 24 65.35
overal survival results
Chemo-radiotherapy for locally advanced head and neck cancer in the elderly population: A 24 22 28.39
unicentric experience
Endoscopy Guided BrachyTherapy (EGBT)for sinonasal and nasopharyngeal recurrences 24 8 17.91
Weekly versus three weekly Cisplatin in postoperative chemoradiotherapy for high risk head 22 19 57.64
and neck cancer
Late toxicity after radical treatment for locally advanced head-and-neck carcinomas. 20 19 38.33
The EXTREME regimen for recurrent/metastatic HNSCC: Treatment outcome in a single 20 18 51.50
institution cohort
Locally advanced head and neck cancer treated with accelerated radiotherapy, Nimorazol 19 17 62.29
and weekly cisplatinum.
Breakthrough pain in head and neck cancer patients undergoing radiotherapy. Treatment with 17 16 34.20
nasal fentanyl.
Phase II study: CT-guided interstitial 60Co-HDR-Brachytherapy with MRI fusion for boost 16 14 87.00
head and neck patient
5

6. Map Over View
6

7. Map Over View
6